| | Promise or peril? impact of the medicare drug benefit on the ESRD populationNo abstract is available. To read the body of this article, please view the Full Text online. |
a Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA  Address correspondence to Mark E. Williams, MD, FACP, Harvard Medical School, 1 Joslin Place, Boston, MA 02215 USA
PII: S1073-4449(04)00013-5 doi:10.1053/j.arrt.2004.02.002 © 2004 National Kidney Foundation, Inc. Published by Elsevier Inc All rights reserved. | |
|
|
